Fisetin inhibits osteoclast differentiation via downregulation of p38 and c-Fos-NFATc1 signaling pathways

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Choi, Sik Won ^a   Son, Young Jin ^b   Yun, Jung Mi ^c   Kim, Seong Hwan ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Sunchon National University   (South Korea)

^c Kwangju Women University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; FISETIN; PROTEIN C FOS; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84867780141     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/810563     Document Type: Article

References (37)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, Osteoporosis prevention, diagnosis, and therapy. The Journal of the American Medical Association 2001 285 6 785 795
2. Lee Z. H., Kim H. H., Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochemical and Biophysical Research Communications 2003 305 2 211 214 2-s2.0-0038706164 10.1016/S0006-291X(03)00695- 8 (Pubitemid 36555454)
3. Huang H., Chang E. J., Ryu J., Lee Z. H., Lee Y., Kim H. H., Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochemical and Biophysical Research Communications 2006 351 1 99 105 2-s2.0-33750330963 10.1016/j.bbrc.2006.10.011 (Pubitemid 44635412)
4. Morabito N., Crisafulli A., Vergara C., Gaudio A., Lasco A., Frisina N., D'Anna R., Corrado F., Pizzoleo M. A., Cincotta M., Altavilla D., Ientile R., Squadrito F., Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. Journal of Bone and Mineral Research 2002 17 10 1904 1912 2-s2.0-0036785298
5. Rassi C. M., Lieberherr M., Chaumaz G., Pointillart A., Cournot G., Down-regulation of osteoclast differentiation by daidzein via caspase 3. Journal of Bone and Mineral Research 2002 17 4 630 638 2-s2.0-0036126929 (Pubitemid 34246638)
6. Bhat T. A., Nambiar D., Pal A., Agarwal R., Singh R. P., Fisetin inhibits various attributes of angiogenesis in vitro and in vivoimplications for angioprevention. Carcinogenesis 2012 33 2 385 393 10.1093/carcin/bgr282
7. Yu S. H., Yang P. M., Peng C. W., Yu Y. C., Chiu S. J., Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. Cancer Letters 2011 300 1 96 104 2-s2.0-78549273307 10.1016/j.canlet.2010.09.015
8. Sengupta B., Banerjee A., Sengupta P. K., Investigations on the binding and antioxidant properties of the plant flavonoid fisetin in model biomembranes. FEBS Letters 2004 570 13 77 81 2-s2.0-3142540615 10.1016/j.febslet.2004.06.027 (Pubitemid 38900960)
9. Kim M. H., Ryu S. Y., Choi J. S., Min Y. K., Kim S. H., Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. Journal of Cellular Physiology 2009 221 3 618 628 2-s2.0-70449707304 10.1002/jcp.21892
10. Lee S. U., Choi Y. H., Kim Y. S., Min Y. K., Rhee M., Kim S. H., Anti-resorptive saurolactam exhibits in vitro anti-inflammatory activity via ERK-NF- κ B signaling pathway. International Immunopharmacology 2010 10 3 298 303 2-s2.0-76849095499 10.1016/j.intimp.2009.11.014
11. Rozen S., Skaletsky H., Primer3 on the WWW for general users and for biologist programmers. Methods in Molecular Biology 2000 132 365 386 2-s2.0-0033990048
12. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-Δ Δ C T method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
13. Yeon J. T., Choi S. W., Park K. I., Choi M. K., Kim J. J., Youn B. S., Lee M. S., Oh J., Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway. Biochemistry and Molecular Biology Reports 2012 45 3 171 176
14. 2+-NFAT signaling. FEBS Letters 2012 586 3 263 269 10.1016/j.febslet.2011.12.033
15. Sharma S. M., Bronisz A., Hu R., Patel K., Mansky K. C., Sif S., Ostrowski M. C., MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. The Journal of Biological Chemistry 2007 282 21 15921 15929 2-s2.0-34447508339 10.1074/jbc.M609723200 (Pubitemid 47093311)
16. Lee S. H., Kim T., Jeong D., Kim N., Choi Y., The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. The Journal of Biological Chemistry 2008 283 17 11526 11534 2-s2.0-45549099188 10.1074/jbc.M708935200
17. Park C. K., Kim H. J., Kwak H. B., Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. International Immunopharmacology 2007 7 12 1507 1516 10.1016/j.intimp.2007.07.016 (Pubitemid 47499256)
18. Kim S. N., Kim M. H., Kim Y. S., Ryu S. Y., Min Y. K., Kim S. H., Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation. Phytotherapy Research 2009 23 2 185 191 2-s2.0-59449103045 10.1002/ptr.2581
19. Kim S. N., Kim M. H., Min Y. K., Kim S. H., Licochalcone A inhibits the formation and bone resorptive activity of osteoclasts. Cell Biology International 2008 32 9 1064 1072 2-s2.0-49749135501 10.1016/j.cellbi.2008.04. 017
20. Kim M. H., Ryu S. Y., Bae M. A., Choi J. S., Min Y. K., Kim S. H., Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food and Chemical Toxicology 2008 46 11 3375 3382 2-s2.0-54449086557 10.1016/j.fct.2008.08.016
21. Asagiri M., Takayanagi H., The molecular understanding of osteoclast differentiation. Bone 2007 40 2 251 264 2-s2.0-33846031926 10.1016/j.bone.2006. 09.023 (Pubitemid 46054562)
22. Kukita T., Wada N., Kukita A., Kakimoto T., Sandra F., Toh K., Nagata K., Iijima T., Horiuchi M., Matsusaki H., Hieshima K., Yoshie O., Nomiyama H., RANKL-induced DC-STAMP is essential for osteoclastogenesis. Journal of Experimental Medicine 2004 200 7 941 946 2-s2.0-5444229284 10.1084/jem.20040518 (Pubitemid 39362930)
23. Yagi M., Miyamoto T., Sawatani Y., Iwamoto K., Hosogane N., Fujita N., Morita K., Ninomiya K., Suzuki T., Miyamoto K., Oike Y., Takeya M., Toyama Y., Suda T., DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. Journal of Experimental Medicine 2005 202 3 345 351 2-s2.0-23744459835 10.1084/jem.20050645 (Pubitemid 41126951)
24. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M., Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF- κ B ligand (RANKL). The Journal of Biological Chemistry 2000 275 40 31155 31161 2-s2.0-0034613188
25. Lee S. E., Woo K. M., Kim S. Y., Kim H. M., Kwack K., Lee Z. H., Kim H. H., The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002 30 1 71 77 2-s2.0-0036138694 10.1016/S8756-3282(01)00657-3 (Pubitemid 34044303)
26. Zwerina J., Hayer S., Redlich K., Bobacz K., Kollias G., Smolen J. S., Schett G., Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis and Rheumatism 2006 54 2 463 472 2-s2.0-32444438052 10.1002/art.21626 (Pubitemid 43228620)
27. Mbalaviele G., Anderson G., Jones A., de Ciechi P., Settle S., Mnich S., Thiede M., Abu-Amer Y., Portanova J., Monahan J., Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. Journal of Pharmacology and Experimental Therapeutics 2006 317 3 1044 1053 2-s2.0-33646808648 10.1124/jpet.105.100362 (Pubitemid 43764107)
28. Wei S., Siegal G. P., p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Advances in Anatomic Pathology 2007 14 1 42 45 2-s2.0-33846002041 10.1097/PAP.0b013e31802ef4f2 (Pubitemid 46052181)
29. Lee J. D., Huh J. E., Jeon G., Yang H. R., Woo H. S., Choi D. Y., Park D. S., Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. International Immunopharmacology 2009 9 3 268 276 2-s2.0-60549095283 10.1016/j.intimp.2008.11.005
30. Inkielewicz-Stepniak I., Radomski M. W., Wozniak M., Fisetin prevents fluoride- and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells. Food and Chemical Toxicology 2012 50 3-4 583 589 10.1016/j.fct.2011.12.015
31. Arai A., Mizoguchi T., Harada S., Kobayashi Y., Nakamichi Y., Yasuda H., Penninger J. M., Yamada K., Udagawa N., Takahashi N., Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. Journal of Cell Science 2012 125 12 2910 2917
32. Wang Z. Q., Ovitt C., Grigoriadis A. E., Mohle-Steinlein U., Ruther U., Wagner E. F., Bone and haematopoietic defects in mice lacking c-fos. Nature 1992 360 6406 741 745 2-s2.0-0027070472 10.1038/360741a0 (Pubitemid 23012271)
33. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., Kumegawa M., Kimura T., Takeya T., Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. The Journal of Biological Chemistry 2002 277 43 41147 41156 2-s2.0-0037174944 10.1074/jbc.M205063200 (Pubitemid 35215706)
34. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J. I., Wagner E. F., Mak T. W., Kodama T., Taniguchi T., Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 2002 3 6 889 901 2-s2.0-18744366041 10.1016/S1534-5807(02) 00369-6 (Pubitemid 35460788)
35. Gelb B. D., Shi G. P., Chapman H. A., Desnick R. J., Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996 273 5279 1236 1238 2-s2.0-0029809357
36. Ishikawa T., Kamiyama M., Tani-Ishii N., Suzuki H., Ichikawa Y., Hamaguchi Y., Momiyama N., Shimada H., Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Molecular Carcinogenesis 2001 32 2 84 91 2-s2.0-0035173085 10.1002/mc.1067 (Pubitemid 33063186)
37. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., Hisatake K., Nogi Y., Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. The Journal of Biological Chemistry 2004 279 44 45969 45979 2-s2.0-8544267975 10.1074/jbc.M408795200 (Pubitemid 39491590)